TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension

Aberrant kinase signaling that involves platelet-derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c-KIT) pathways may be responsible for vascular remodeling in pulmonary arterial hypertension. Targeting these specific pathways m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Robert P. Frantz, Raymond L. Benza, Richard N. Channick, Kelly Chin, Luke S. Howard, Vallerie V. McLaughlin, Olivier Sitbon, Roham T. Zamanian, Anna R. Hemnes, Matt Cravets, Jean-Marie Bruey, Robert Roscigno, David Mottola, Erin Elman, Lawrence S. Zisman, Hossein-Ardeschir Ghofrani
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Diseases of the circulatory (Cardiovascular) system
RC666-701
Diseases of the respiratory system
RC705-779
Acceso en línea:https://doaj.org/article/e7c6ee3ea34a41f89721a2c6c04b54de
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/e7c6ee3ea34a41f89721a2c6c04b54de

Ejemplares similares